Miura S
Gan No Rinsho. 1984 Sep;30(12 Suppl):1578-86.
Second primary malignancy experience was examined for 2,427 primary breast cancer during 1964-1982. There were 72 cases observed which developed a second malignancy after the treatment of antecedent breast cancer. Annual accumulated incidences of double cancer regressed on a linear equation of Y = 0.43X + 0.36, and expected incidence for 5 years was 2.5%, for 10 years 4.7% and for 15 years 6.8%, respectively. Calculating the expected cancer morbidity in person-years method, we found that the observed incidence of double cancer was higher than that expected; the ratio of O/E was 1.40. The opposite brest cancer was mainly responsible for this higher risk (O/E ratio was 6.37). Also the higher risks were pointed out for cancer of uterine corpus and ovary. MMC and CPA was given as surgical adjuvants for one third of the patients. The results analysed by person-years method showed there were no increased incidences of second malignancy in chemotherapy groups compared with the control group.
对1964年至1982年间的2427例原发性乳腺癌患者的第二原发性恶性肿瘤情况进行了研究。有72例患者在先行乳腺癌治疗后发生了第二种恶性肿瘤。双癌的年累积发病率按照Y = 0.43X + 0.36的线性方程进行回归分析，5年的预期发病率为2.5%，10年为4.7%，15年为6.8%。采用人年法计算预期癌症发病率，我们发现双癌的观察发病率高于预期；观察值与预期值之比（O/E）为1.40。这种较高风险主要由对侧乳腺癌导致（O/E比为6.37）。子宫体癌和卵巢癌也存在较高风险。三分之一的患者接受了丝裂霉素（MMC）和顺铂（CPA）作为手术辅助治疗。用人年法分析结果显示，与对照组相比，化疗组第二原发性恶性肿瘤的发病率没有增加。
